Markets

Comment

Indian pharma deals landscape shaped by Covid-19

The number of deals made in the Indian pharma market increased by 22% from 2019 to 2020, likely due to the Covid-19 pandemic.

GlobalData Healthcare

Features

Why Covid-19 didn’t hurt tech brands’ appetite for Asian investment

Comment

Novartis aiming to expand patient reach for world’s most expensive drug, Zolgensma

Comment

Microbiome-targeting pipeline addresses multiple immunological indications

Comment

EHA 2021: primary endpoints met in final analysis of EURO-SKI trial in CML

Comment

Novavax’s Covid-19 vaccine may face severe uptake challenges in the US

Comment

Interim data from tenapanor’s OPTIMIZE trial signals promising option for CKD-HP

Comment

Covid-19 vaccine purchasing in EU likely to pivot to traditional reimbursement models from 2023

Comment

Boehringer’s BI 425809 hints at cognitive improvement in schizophrenia patients

GlobalData Healthcare

Comment

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

GlobalData Healthcare

Comment

Novel narcolepsy product faces safety barriers to being competitive

GlobalData Healthcare

Comment

Long-acting drugs to shake up GHD in 3MM

GlobalData Healthcare

Comment

Arcutis presents topline Phase III roflumilast data at EADV spring 2021

GlobalData Healthcare

Comment

Endometrial cancer patients expected to benefit from novel advancements in the market

GlobalData Healthcare

Comment

AAN 2021: Impel’s INP104 could restore underused nasal delivery for acute migraine

GlobalData Healthcare

Comment

Chinese checkpoint inhibitors are poised to change global IO markets

Comment

Another domestic Chinese PD-1 inhibitor enters the race for US approval following Coherus BioSciences’ deal with Shanghai Junshi Biosciences

GlobalData Healthcare

Comment

Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval

GlobalData Healthcare

Features

Top ten pharma companies in 2020